Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAetna fibrinogen concentrate Coverage & Prior Auth…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0792

    Human Fibrinogen Concentrate (RiaSTAP and Fibryga)

    Customize your policy alerts

    Sign up for Aetna Policy 0792 alerts

    Get alerted when Policy 0792 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, precertification, approved indications, dosing guidance, and excluded indications for human fibrinogen concentrates RiaSTAP and Fibryga for commercial medical plans.

    Policy Summary
    PayerAetna
    PolicyHuman Fibrinogen Concentrate (RiaSTAP and Fibryga)
    Policy CodePolicy 0792
    Change TypeNo material changes
    Effective DateAug 21, 2009
    Last ReviewJan 25, 2024
    Next Review DateDec 12, 2024
    Key ActionObtain precertification from Aetna's Special Case Precert Unit and document diagnosis, indication, dosing plan, and supporting fibrinogen/viscoelastic data.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Precert requiredPrecertification required
    Congenital CFDFDA-approved indication
    70 mg/kgEmpiric dosing
    J7177/J7178Covered HCPCS
    Acquired hypofibrinogenemiaExperimental uses
    01/25/2024Last review

    Coverage criteria for human fibrinogen concentrate

    Fibryga Initial Approval

    Fibryga — Covered when ANY of the following are met:

    Fibryga: Acute bleeding in congenital fibrinogen deficiency: Treatment of acute bleeding episodes in members with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

    All other indications considered experimental/investigational.

    RiaSTAP Initial Approval

    RiaSTAP — Covered when ANY of the following are met:

    RiaSTAP: Acute bleeding: Treatment of acute bleeding episodes in members with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

    FDA-licensed for this indication.

    RiaSTAP: Perioperative management:
    Policy Summary
    PayerAetna
    PolicyHuman Fibrinogen Concentrate (RiaSTAP and Fibryga)
    Policy CodePolicy 0792
    Change TypeNo material changes
    Effective DateAug 21, 2009
    Last ReviewJan 25, 2024
    Next Review DateDec 12, 2024
    Key ActionObtain precertification from Aetna's Special Case Precert Unit and document diagnosis, indication, dosing plan, and supporting fibrinogen/viscoelastic data.
    SourceLink
    On This Page
    Coverage criteria for human fibrinogen concentrateCoding, dosing and dose-calculation guidancePrior authorization, documentation and operational guidanceBackground and clinical contextDefinitions and regulatory indicationsPolicy revision history
    Perioperative management of bleeding in members with a diagnosis of afibrinogenemia.

    Compendial/label-supported perioperative use for afibrinogenemia.

    RiaSTAP: Prophylaxis: Prophylaxis to reduce the frequency of bleeding episodes in members with afibrinogenemia (requires justification in the medical record).

    Continuation of prophylaxis requires documented clinical benefit (e.g., reduced bleeding frequency).

    Continuation of Therapy

    Continuation of therapy — Covered when ALL of the following are met:

    Continuation general: Member meets the initial medical necessity selection criteria for the prescribed fibrinogen concentrate product and requests reauthorization.

    Applies to existing and new members requesting continuation; documentation must support the original indication.

    Continuation for prophylaxis (RiaSTAP): For RiaSTAP prophylaxis in afibrinogenemia, the member must demonstrate clinical benefit from therapy (for example, a documented reduction in frequency of bleeding episodes).

    Medical records must document benefit to justify ongoing prophylactic use.

    Covered clinical scenarios

    Coverage supported for the following clinical scenarios when criteria are documented:

    Congenital fibrinogen deficiency (CFD): Documented diagnosis of afibrinogenemia or hypofibrinogenemia AND an acute bleeding episode or clinical need for fibrinogen replacement.clinical diagnosis; very low fibrinogen levels typical

    RiaSTAP is FDA-licensed for this indication; phase II data support target attainment with 70 mg/kg.

    Viscoelastic-guided perioperative or trauma bleeding management: Clinically relevant coagulopathic bleeding AND viscoelastic testing (e.g., ROTEM/TEG/FIBTEM) demonstrating low fibrin-based clot firmness guiding fibrinogen concentrate administration.abnormal ROTEM/TEG/FIBTEM per institutional trigger

    Targeted, point-of-care guided dosing has been used to reduce transfusion requirements in perioperative studies.

    Obstetric hemorrhage with low fibrinogen: Parturient with primary postpartum hemorrhage AND fibrinogen level below suggested thresholds where fibrinogen concentrate is considered as part of hemostatic management.fibrinogen <1.0 g/L (or consideration when <1.5–2.0 g/L)

    Evidence incomplete; some guidance suggests treatment when fibrinogen is markedly low.

    Selected prophylactic use in cardiac surgery: Pre-operative fibrinogen concentrate administration in selected CABG patients with low pre-operative fibrinogen to reduce post-operative bleeding, when supported by trial criteria.pre-op fibrinogen <3.8 g/L as used in cited pilot study

    Pilot RCT (2 g) showed reduced bleeding; larger confirmatory studies are needed.

    Coverage criteria — congenital fibrinogen deficiency

    Covered when ALL of the following are met for congenital fibrinogen deficiency (based on FDA approval and label guidance):

    Indication and diagnosis: Documented congenital afibrinogenemia or hypofibrinogenemia consistent with the product's FDA-approved indication.

    Fibryga is FDA-approved for acute bleeding episodes in adults and adolescents with CFD.

    Clinical need and bleeding: Member is experiencing an acute bleeding episode requiring fibrinogen replacement or has a peri-procedural bleeding risk where supplementation is clinically indicated.

    Dosing should be individualized to the extent of bleeding.

    Laboratory support and monitoring: Pre- and post-treatment fibrinogen plasma level measurements (or validated viscoelastic measures) documented to justify dosing and monitor response; target levels: 100 mg/dL for minor bleeding and 150 mg/dL for major bleeding with lower acceptable limits for repeat dosing as per prescribing information.target 100 mg/dL (minor), 150 mg/dL (major); lower limits 80/130 mg/dL respectively

    Monitor and give additional infusions if levels remain below targets until hemostasis is achieved.

    Coverage stance — peri-operative/trauma acquired hypofibrinogenemia

    Considered experimental/insufficient evidence when used routinely for peri-operative or trauma-associated acquired hypofibrinogenemia unless specific criteria met:

    Peri-operative/trauma use evidence: Routine peri-operative or trauma-associated use is not supported by consistent evidence of mortality or other definitive clinical outcome benefit despite reductions in transfusion in some analyses; use should be limited to settings with documented acquired hypofibrinogenemia and when standard therapies (e.g., cryoprecipitate) are unsuitable or contraindicated.documented acquired hypofibrinogenemia or compelling clinical justification

    Large RCTs (e.g., FIBRES) are ongoing/needed to clarify comparative effectiveness.

    Coverage considerations and evidence-based stance

    Coverage supported under circumstances where evidence indicates potential benefit or established indication:

    Approved/Supported Indications: Use for congenital fibrinogen deficiency and situations with documented hypofibrinogenemia and active bleeding or high-risk peri-operative bleeding where targeted replacement is guided by laboratory or viscoelastic testing to restore physiological fibrinogen levels.documented low fibrinogen or abnormal viscoelastic testing

    Supported by licensing, clinical trials and consensus statements; targeted use favored over routine prophylaxis.

    Not supported as routine prophylaxis: Routine prophylactic administration (for example, in patients without documented hypofibrinogenemia) is not supported by current randomized evidence and is not recommended as standard care.absence of documented deficiency and prophylactic intent

    RCTs in PPH and perioperative settings did not demonstrate routine benefit for systematic early administration.

    Postpartum hemorrhage (PPH): Systematic early administration of fixed 2–3 g fibrinogen concentrate in normofibrinogenemic PPH patients did not reduce transfusion or clinical failure in RCTs; targeted use in patients with documented low fibrinogen or ongoing severe bleeding may be considered but evidence remains insufficient for routine use.PPH with documented hypofibrinogenemia or protocolized targeted therapy

    Trials (Wikkelso, Ducloy-Bouthors) found no routine benefit from early fixed-dose therapy.

    Trauma-associated hemorrhage: Randomized and observational data do not show a consistent mortality benefit; fibrinogen concentrate can be used as part of goal-directed therapy when hypofibrinogenemia is documented and guided by viscoelastic testing, recognizing evidence quality is low-to-moderate and further trials are needed.trauma with documented hypofibrinogenemia or ROTEM trigger

    Systematic reviews/meta-analyses report no mortality advantage but potential transfusion-sparing effects; timely administration in trauma remains a challenge.

    Aetna considers human fibrinogen concentrate to be experimental and investigational for several acquired or non-congenital indications because effectiveness has not been established. Examples listed in the policy include: acquired hypofibrinogenemia, bleeding associated with aortic reconstruction and deep hypothermic circulatory arrest, dysfibrinogenemia, intra-operative use to prevent bleeding in neonatal and infant cardiac surgery, obstetric hemorrhage including postpartum hemorrhage in persons without congenital fibrinogen deficiency, and trauma-associated hemorrhage in persons without congenital fibrinogen deficiency.

    RiaSTAP is not indicated for dysfibrinogenemia. The FDA licensing and the policy specify that RiaSTAP is indicated for treatment of acute bleeding episodes in congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia) and explicitly note that it is not indicated for dysfibrinogenemia.

    Fibryga's FDA approval covers acute bleeding in congenital fibrinogen deficiency, and the product label explicitly excludes dysfibrinogenemia. Fibryga is therefore not indicated for treatment of dysfibrinogenemia.

    Routine prophylactic administration of fibrinogen concentrate is not supported when there is no documented hypofibrinogenemia or active bleeding. Randomized trials and meta-analyses in peri-operative and other settings have not consistently demonstrated improvements in major clinical outcomes, and current evidence supports targeted, not routine, prophylactic use.

    This Clinical Policy Bulletin provides a general description of coverage positions and clinical guidance and is descriptive, not a contract. Coverage for a member is subject to the terms and provisions of the individual benefit plan, including applicable member eligibility, plan exclusions, and any program-specific rules.

    Fibrinogen concentrate may be considered for non-congenital clinical scenarios when documented criteria are met. Examples discussed in the policy include management of acquired hypofibrinogenemia guided by laboratory or viscoelastic testing, obstetric hemorrhage with documented low fibrinogen, and selected perioperative situations where targeted replacement is indicated. However, many non-congenital uses are listed among experimental/investigational indications and specific ICD-10 codes for non-covered scenarios (e.g., D65, postpartum hemorrhage codes) are noted in the policy unless individual criteria and documentation justify coverage.

    Routine replacement of fibrinogen concentrate without laboratory evidence of deficiency or without documentation of bleeding risk or targeted viscoelastic parameters is not supported. Guidelines and systematic reviews highlight the need for prospective randomized data and clear thresholds to justify routine replacement, so use for routine prophylaxis in normofibrinogenemic patients would not meet medical necessity.

    Current randomized evidence does not support routine peri-operative administration of fibrinogen concentrate for cardiovascular surgery to improve mortality or other definitive clinical outcomes. Although some trials report reduced allogeneic red blood cell transfusion, the evidence is insufficient to recommend routine prophylactic peri-operative use without documented deficiency or targeted testing.

    Pre-emptive administration of fixed doses (e.g., 2–3 g) of fibrinogen concentrate in normofibrinogenemic patients with postpartum hemorrhage has not demonstrated a reduction in transfusion or clinical failure in randomized trials. Multiple RCTs and systematic reviews found no significant benefit for routine early systematic administration in this population.

    Coding, dosing and dose-calculation guidance

    Covered HCPCS and related CPT codes when selection criteria are metmixedCovered
    J7177Injection, human fibrinogen concentrate (fibryga), 1 mg
    J7178Injection, human fibrinogen concentrate, not otherwise specified, 1 mg [RiaSTAP]
    85384Fibrinogen; activity
    85385Fibrinogen; antigen
    96374Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance/drug
    96375Therapeutic injection; each additional sequential intravenous push of a new substance/drug
    96376Therapeutic injection; each additional sequential intravenous push of the same substance/drug
    96379Unlisted therapeutic; prophylactic, or diagnostic IV or intra-arterial injection or infusion
    ICD-10 codes covered if selection criteria are metICD-10Covered
    D68.2Hereditary deficiency of other clotting factors [congenital fibrinogen deficiency]
    D68.8Other specified coagulation defects
    ICD-10 codes not covered for indications listed in CPB (not all-inclusive)ICD-10Not Covered
    D65Disseminated intravascular coagulation [defibrination syndrome]
    D78.01
    D78.02
    D78.21
    D78.22
    E36.01
    E36.02
    G97.31
    G97.32
    G97.51
    1–10 of 18
    1/2
    Codes referenced in this sectionmixed
    No codes listed
    No explicit codes in this sectionmixed
    No codes listed
    inv-22: Empiric weight-based dosing — 70 mg/kg when fibrinogen level is not known
    Empiric weight-based dosing70 mg/kg body weight recommended when fibrinogen level is not known (applies to Fibryga and RiaSTAP)
    Context of useUsed as an initial empiric IV dose when immediate fibrinogen measurement is unavailable
    Source productsSpecified for both Fibryga (Octapharma) and RiaSTAP (CSL Behring)
    inv-23: Dose calculation when level known (Fibryga) — formula provided
    Fibryga dose calculation (known level)Dose (mg/kg) = (Target fibrinogen level (mg/dL) – measured fibrinogen level (mg/dL)) / 1.8
    Recommended targetsTargets referenced by Fibryga prescribing information: 100 mg/dL (minor bleeding) and 150 mg/dL (major bleeding)
    Dosing individualizationDosing, duration and frequency should be individualized based on extent of bleeding and laboratory values
    inv-24: Dose calculation when level known (RiaSTAP) — formula provided
    RiaSTAP dose calculation (known level)Dose (mg/kg) = (Target fibrinogen level (mg/dL) – measured fibrinogen level (mg/dL)) / 1.7
    Regulatory noteRiaSTAP licensed for treatment of acute bleeding in congenital fibrinogen deficiency; dosing guidance derived from product data and studies
    Clinical useFormula enables calculation of mg/kg dose to reach target fibrinogen level from measured level
    inv-25: Fibrinogen level triggers discussed — obstetric/threshold guidance
    Obstetric threshold (suggested)Authors suggest treating obstetric hemorrhage when fibrinogen <1.0 g/L (100 mg/dL); some reviews suggest considering treatment when <1.5–2.0 g/L
    Trial entry thresholdFIB-PPH and related trials have varied entry criteria; FIB-PPH trial protocol included severe PPH enrollment criteria rather than a single fibrinogen cutoff
    Evidence statusGuidance and trials (FIB-PPH) exist but evidence remains incomplete; randomized results to date have not shown routine early systematic benefit
    inv-26: Target fibrinogen level (minor/major bleeding)
    Target fibrinogen for minor bleeding100 mg/dL (1.0 g/L)
    Target fibrinogen for major bleeding150 mg/dL (1.5 g/L)
    Lower acceptable limits for repeat dosingRepeat dosing if below 80 mg/dL for minor bleeding or 130 mg/dL for major bleeding (per Fibryga PI)
    inv-27: Dose example used in studies — 70 mg/kg common
    Common study dose example70 mg/kg IV was used as the dose in phase II/approval studies (e.g., RiaSTAP pharmacokinetic/pharmacodynamic studies and Fibryga trials)
    Observed incrementA 70 mg/kg dose was observed to increase fibrinogen concentration by approximately 100–125 mg/dL in study populations (median IVR ~1.8 mg/dL per mg/kg for Fibryga)
    Clinical application70 mg/kg is used both in congenital CFD treatment and as an empiric perioperative/bleeding dose in several pilot studies
    inv-28: ROTEM FIBTEM A5 and Clauss fibrinogen correlation thresholds seen in study
    ROTEM–Clauss correlation observedStudy found FIBTEM A5 ≈ 6 mm corresponded with Clauss fibrinogen ≈ 1.7 g/L (170 mg/dL)
    Clinical implicationA FIBTEM A5 threshold around 6 mm may identify hypofibrinogenemia and prompt fibrinogen replacement guided by viscoelastic testing
    TimingROTEM FIBTEM A5 permitted rapid point-of-care assessment with median 22 minutes to FC administration in the cited trauma series

    Prior authorization, documentation and operational guidance

    Prior Authorization

    Prior Authorization Required

    Precertification of human fibrinogen concentrate (Fibryga, RiaSTAP) is required for all Aetna participating providers and members in applicable plan designs. Precertification/authorization must be obtained from Aetna’s Special Case Precert Unit at (855) 888-9046 prior to administration.

    • Affected products: Fibryga, RiaSTAP
    • Affected HCPCS: J7177/J7178 (where applicable)
    Prior Authorization

    Prior Authorization Requirements

    Prior authorization requests must include the clinical indication (e.g., congenital fibrinogen deficiency or specific clinical scenario), planned dose, duration of therapy, and supporting clinical documentation demonstrating medical necessity.

    • Planned dose and duration per FDA labeling or individualized dosing rationale
    • Clinical documentation to justify off-label uses if requested
    Prior Authorization

    Prior Authorization — Non‑Congenital Indications

    Use of human fibrinogen concentrate for non-congenital indications (e.g., acquired hypofibrinogenemia, trauma-associated hemorrhage, postpartum hemorrhage, peri-operative prophylaxis) may require prior authorization and is subject to evidence review; many of these indications are considered experimental/investigational or evidence-dependent and may be non-covered.

    • Acquired hypofibrinogenemia — often experimental/INV
    • Post-partum hemorrhage and trauma — limited or conflicting evidence; authorization not guaranteed
    Denial Risk

    Experimental / Investigational Indications — Denial Risk

    Aetna considers human fibrinogen concentrate experimental and investigational for listed indications where effectiveness is not established; requests for these indications may be denied.

    • Examples: acquired hypofibrinogenemia, obstetric hemorrhage (PPH) in persons without congenital deficiency, trauma-associated hemorrhage in persons without congenital deficiency, intra-operative prophylactic use in neonatal/infant cardiac surgery
    Denial Risk

    Evidence‑Dependent Authorization Risk

    Authorization decisions for non‑FDA or evidence‑limited uses are evidence‑dependent. Lack of demonstrated clinical benefit, insufficient documentation, or use outside approved indications may result in denial.

    • Requests lacking supporting clinical trial data or clear documentation of benefit may be denied
    • Continuation requests must demonstrate ongoing benefit per initial criteria
    Denial Risk

    PPH Outcomes and Timing Considerations

    For postpartum hemorrhage (PPH), randomized and observational data have not consistently shown improved maternal outcomes with routine early administration of fibrinogen concentrate; timing of administration may affect outcomes and delayed use (>3 hours after transfusion start) has been associated with worse outcomes in some analyses.

    • Early, systematic 3 g administration did not reduce transfusion needs or blood loss in a randomized trial (Ducloy‑Bouthors et al.)
    • Observational data suggest administration >3 hours after RBC transfusion start associated with higher risk of near‑miss or death
    Documentation Required

    Required Clinical Documentation

    Clinical documentation submitted with prior authorization should include diagnosis, relevant lab values, prior therapies (e.g., plasma, cryoprecipitate), rationale for fibrinogen concentrate over alternatives, and notes on expected benefit.

    • Diagnosis (congenital fibrinogen deficiency or clinical scenario)
    • Prior and concurrent hemostatic therapies and responses
    • Rationale for product selection (e.g., viral inactivation, rapid administration)
    Documentation Required

    Required Clinical Documentation and Monitoring

    Dosing, frequency, and monitoring must be individualized and supported by laboratory testing and clinical condition. Include documentation of target fibrinogen levels, monitoring plan, and response to treatment.

    • Recommended targets (per Fibryga labeling): ~100 mg/dL for minor bleeding; ~150 mg/dL for major bleeding; retreat if below lower limits
    • Documented plan for monitoring fibrinogen activity and clinical hemostasis
    Documentation Required

    Testing and Timing Documentation

    When used in acquired or peri‑operative settings, objective laboratory testing and timing must be documented (e.g., Clauss fibrinogen, ROTEM/TEG FIBTEM A5) and the interval between testing and product administration should be recorded to support individualized dosing decisions.

    • Include fibrinogen activity (Clauss) and/or ROTEM/TEG FIBTEM A5 values with timestamps
    • Document time from lab/point‑of‑care result to product administration
    Step Therapy

    Step‑Therapy Considerations vs Cryoprecipitate

    Step‑therapy considerations: clinicians should document why plasma or cryoprecipitate are not appropriate or sufficient if fibrinogen concentrate is requested in place of or prior to these alternatives; comparative trial data are limited and payers may require justification.

    • If bypassing cryoprecipitate, provide clinical rationale (safety, supply, speed, viral inactivation)
    • Comparative evidence is limited — authorization may require additional documentation
    Note

    Consider Alternative Therapies

    Consider alternative therapies (e.g., cryoprecipitate, plasma) where supported by evidence or local practice guidelines; documentation should explain why alternatives are not suitable when seeking coverage for fibrinogen concentrate.

    • Cryoprecipitate is the standard intervention for acquired hypofibrinogenemia in many settings
    • Provide justification when opting for fibrinogen concentrate (e.g., rapid availability, standardized dosing)
    Note

    Prior Authorization Reference and Operational Notes

    For operational questions and submission instructions, refer to Aetna’s Clinical Policy Bulletin process and contact the Special Case Precert Unit. Administrative or documentation deficiencies on the prior authorization submission may lead to delayed processing or denial.

    • Contact: Aetna Special Case Precert Unit (855) 888‑9046
    • See Clinical Policy Bulletin and policy history for submission details

    Background and clinical context

    Fibrinogen (Factor I) is essential for clot formation, and inherited quantitative deficiencies (afibrinogenemia and hypofibrinogenemia) and qualitative defects (dysfibrinogenemia) can affect hemostasis. Congenital fibrinogen deficiency is rare; both RiaSTAP and Fibryga are FDA-approved for treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, reflecting the established role of fibrinogen replacement in this population.

    Definitions and regulatory indications

    inv-51: Congenital fibrinogen deficiency (CFD) — definitions of quantitative and qualitative defects
    CFD quantitative defectsType I deficiencies (quantitative): afibrinogenemia and hypofibrinogenemia—low or unmeasurable immunoreactive fibrinogen
    CFD qualitative defectsType II deficiencies (qualitative): dysfibrinogenemia and hypodysfibrinogenemia—normal or altered antigen with reduced coagulant activity
    Clinical consequencesQuantitative deficiencies can cause severe bleeding and/or thrombotic events; dysfibrinogenemia may be asymptomatic or cause bleeding/thrombosis
    inv-52: FDA-approved indications — Fibryga and RiaSTAP approvals for acute bleeding in congenital fibrinogen deficiency
    Fibryga FDA indicationIndicated for treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia); not indicated for dysfibrinogenemia
    RiaSTAP FDA indicationIndicated for treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia); not indicated for dysfibrinogenemia
    RiaSTAP licensing noteRiaSTAP licensed by FDA on January 16, 2009 for acute bleeding in CFD based on phase II data
    inv-53: Congenital fibrinogen disorders (CFD) — inherited quantitative/qualitative abnormalities summary
    Inherited abnormalities summaryCongenital fibrinogen disorders include quantitative (afibrinogenemia, hypofibrinogenemia) and qualitative (dysfibrinogenemia, hypodysfibrinogenemia) abnormalities
    Clinical manifestationsThese disorders can cause bleeding, thrombosis, or be asymptomatic depending on type and severity
    Replacement therapiesReplacement options include frozen plasma, cryoprecipitate, or fibrinogen concentrate; concentrates offer standardized dosing and viral inactivation
    inv-54: RiaSTAP indication — licensed for treatment of acute bleeding in congenital fibrinogen deficiency
    RiaSTAP licensed indicationLicensed for treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia)
    ExclusionRiaSTAP is not indicated for dysfibrinogenemia
    Basis of approvalApproval based on phase II study showing target attainment with 70 mg/kg and improved MCF
    inv-55: Target fibrinogen plasma levels — 100 mg/dL (minor) and 150 mg/dL (major)
    Target for minor bleeding100 mg/dL (1.0 g/L)
    Target for major bleeding150 mg/dL (1.5 g/L)
    Lower limits for repeat dosingRepeat dosing if below 80 mg/dL (minor) or 130 mg/dL (major) until hemostasis achieved
    inv-56: Acquired hypofibrinogenemia — peri-operative/trauma-associated definitions and clinical thresholds
    Definition (clinical)Acquired hypofibrinogenemia: peri-operative or trauma-associated decrease in plasma fibrinogen often defined as fibrinogen <1.5–2.0 g/L associated with increased bleeding risk in cardiac surgery
    Standard comparatorCryoprecipitate is the standard intervention for acquired hypofibrinogenemia; fibrinogen concentrate is an alternative under study
    Evidence statusRandomized trials and meta-analyses show reduced RBC transfusion but no consistent mortality benefit; routine peri-operative use not established
    inv-57: ROTEM FIBTEM A5 — definition and use as point-of-care viscoelastic parameter
    Definition and useROTEM FIBTEM A5 is a viscoelastic point-of-care parameter assessing fibrin-based clot firmness used to identify hypofibrinogenemia and guide fibrinogen replacement
    Operational threshold exampleFIBTEM A5 around 6 mm corresponded to Clauss fibrinogen ~1.7 g/L in a trauma series
    Clinical roleEnables rapid testing and goal-directed administration of fibrinogen concentrate in bleeding patients
    inv-58: Severe postpartum hemorrhage (PPH) — trial definitions and enrollment characteristics
    Trial definitionsSevere PPH trials enrolled patients with large ongoing blood loss and defined eligibility by clinical criteria (e.g., blood loss ≥500–1,000 mL depending on delivery type) rather than a single fibrinogen cutoff
    Interventions studiedTrials evaluated pre-emptive or early fixed-dose fibrinogen concentrate (e.g., 2–3 g) versus placebo for PPH
    Outcome summaryRandomized trials to date did not show reduced transfusion or improved major clinical outcomes with routine early fixed-dose administration
    inv-59: RiaSTAP / Fibryga and related guidance — FDA PI and MASAC guidance referenced
    Regulatory and guidance sourcesFDA prescribing information for RiaSTAP and Fibryga provide approved indications and dosing; MASAC and other consensus statements address management of congenital fibrinogen deficiency
    Label exclusionsBoth products are not indicated for dysfibrinogenemia as noted in FDA labeling
    Clinical evidence baseProduct approvals and dosing recommendations are supported by FORMA and RiaSTAP clinical studies cited in the prescribing information and references

    Policy revision history